Corcept Wins U.S. Approval for First Drug to Treat Cushing’s Syndrome
http://www.bloomberg.com/news/2012-02-17/corcept-wins-u-s-approval-for-first-drug-to-treat-cushing-s-syndrome.html
Corcept Therapeutics Inc. (CORT) won U.S. approval for a drug that uses the active ingredient of the abortion pill RU-486 to treat Cushings Syndrome.
The Food and Drug Administration cleared Korlym, formerly called Corlux, to treat the syndrome in patients who have Type 2 diabetes or glucose intolerance and arent candidates for surgery or havent responded to surgery, the agency said today in a statement. Korlym, the leading drug candidate from Menlo Park, California-based Corcept, is the first therapy approved for the hormone condition, the FDA said.
Korlym, a once-daily pill, will be available on May 1 through a small number of endocrinologists who treat patients affected with the disease, Joseph Belanoff, Corcepts chief executive officer, said today in a statement.
These doctors can be reached without a large sales and marketing infrastructure, he said.